Page 3 - Trisha Roy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pharmacies pull J&J sunscreens off shelves after carcinogen found in some sprays 07/15/2021 | 05:15pm EDT Send by mail : Message : Required fields (Reuters) -Pharmacy chains CVS Health, Walgreens Boots Alliance and retailer Walmart Inc began pulling Johnson & Johnson's sunscreen products off their shelves after J&J said it had detected a cancer-causing chemical in some samples. Pharmaceutical and consumer goods company J&J on Wednesday voluntarily recalled five Neutrogena and Aveeno brand aerosol sunscreens and advised consumers to stop using the products and discard them after internal testi...

By Syndicated Content By Carl O’Donnell and Trisha Roy (Reuters) -The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc’s Alzheimer’s drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat. The FDA last week called for an independent federal probe into its representatives’ interactions with Biogen ahead of the regulator’s approval of Aduhelm last month. “The accelerated approval was based on very solid grounds,â€...

By Syndicated Content Jul 14, 2021 | 3:06 PM (Reuters) – The United States has administered 335,487,779 doses of COVID-19 vaccines in the country as of Wednesday morning and distributed 388,295,385 doses, the U.S. Centers for Disease Control and Prevention said on Wednesday. Those figures are up from the 334,942,236 vaccine doses the CDC said had gone into arms by July 13, out of 387,241,530 doses delivered. The agency said 184,835,149 people had received at least one dose, while 160,126,516 people are fully vaccinated as of Wednesday. The CDC tally includes two-dose vaccines...

Message : Required fields July 12 (Reuters) - The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator. The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta) © Reuters 2021 07/12

U.S. starts national Medicare coverage policy review for Biogen's Aduhelm 07/12/2021 22:09 (Reuters) -The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator. The Centers for Medicare & Medicaid Services (CMS) expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H) Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged ...